The secretome of lung resident mesenchymal stem cells is anti-fibrotic in vitro and in vivo

Khan, Petra; Gazdhar, Amiq; Fytianos, Kleanthis; Fang, Lei; Caldana, Fabienne; Roth, Michael; Tamm, Michael; Geiser, Thomas; Hostettler, Katrin

doi:10.1183/13993003.congress-2018.pa594

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs display immunomodulatory properties and can secrete anti-fibrotic factors (Figure 4). It has been reported that lung resident MSC can be in IPF lungs and their secretome is able to damage fibroblast proliferation while promoting enhanced epithelial wound repair via several growth factors, among which hepatocyte growth factor (HGF) (266,267). Interestingly, inhaled lung spheroid cellsecretome (LSC-Sec) and exosomes (LSC-Exo) have been shown to attenuate bleomycin and silica-induced fibrosis in experimental models in a more effective manner that those derived from resident MSCs.…”

Section: Advanced Cell Therapiesmentioning

confidence: 99%

The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review

Stella¹,

D’Agnano²,

Piloni³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background and Objective: Translational research is a source of continuous innovation in medicine, more particularly for clinical research on new treatment modalities in idiopathic pulmonary fibrosis (IPF) patients.However, the heterogeneity of the disease is well recognized, and different pathological and molecular settings have been identified. The molecular mechanisms by which IPF proceeds in time and space remains poorly understood. Although some IPF features are reminiscent of cancer, the dynamics of malignant divergent clonal selective pressure and heterogeneity clearly differ from those occurring in IPF. This is reflected in the absence of patient proper selection and stratification to biological agents (pirfenidone, nintedanib) which limit therapeutic efficacy. Consequently, increased costs are related to the clinical management of advanced IPF patients. Steady collaboration and fluid communication between pneumo-oncologists, radiologists and molecular biologists is a clear priority for the correct interpretation of tests and the definition of effective personalized strategies against this orphan disease. The present work aims at providing the most relevant hints shared by cancer and IPF.Methods: A systematic literature review was performed to identify all relevant data. The examined databases were Scopus, Web of Science, Cochrane, Google Scholar, and PubMed. The last search was run on January 5, 2022. We have primarily conducted separated research for lung cancer, IPF, genetics, epigenetics, surgery in IPF and cancer.

show abstract

Section: Advanced Cell Therapiesmentioning

confidence: 99%

The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review

Stella¹,

D’Agnano²,

Piloni³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…Nevertheless, secretomes have several notable therapeutic effects that make them a valid option for accelerating the recovery of patients with COVID-19. Khan et al revealed that bleomycin-injured rats treated with MSC secretomes had an improved lung architecture, and suppressed α-SMA and collagen content, concluding that MSC secretomes were enriched with many bioactive substances with anti-inflammatory, immunosuppressive, and angiogenic properties that helped the lung to recover [ 113 ]. Felix et al also demonstrated that rats with bleomycin-induced lung injury demonstrated better regeneration after treatment with MSCs and MSC-conditioned media [ 114 ].…”

Section: Msc-free Therapy For Sars-cov-2mentioning

confidence: 99%

Potential Cell-Based and Cell-Free Therapy for Patients with COVID-19

Tan

Alfarafisa

Septiani

et al. 2022

Cells

View full text Add to dashboard Cite

Since it was first reported, the novel coronavirus disease 2019 (COVID-19) remains an unresolved puzzle for biomedical researchers in different fields. Various treatments, drugs, and interventions were explored as treatments for COVID. Nevertheless, there are no standard and effective therapeutic measures. Meanwhile, mesenchymal stem cell (MSC) therapy offers a new approach with minimal side effects. MSCs and MSC-based products possess several biological properties that potentially alleviate COVID-19 symptoms. Generally, there are three classifications of stem cell therapy: cell-based therapy, tissue engineering, and cell-free therapy. This review discusses the MSC-based and cell-free therapies for patients with COVID-19, their potential mechanisms of action, and clinical trials related to these therapies. Cell-based therapies involve the direct use and injection of MSCs into the target tissue or organ. On the other hand, cell-free therapy uses secreted products from cells as the primary material. Cell-free therapy materials can comprise cell secretomes and extracellular vesicles. Each therapeutic approach possesses different benefits and various risks. A better understanding of MSC-based and cell-free therapies is essential for supporting the development of safe and effective COVID-19 therapy.

show abstract

“…12 On the other hands, lung resident MSCs secretome has anti-fibrotic effects. 13 Therefore, caution should be exercised in the administration of MSCs to attenuate the progression of pulmonary fibrosis. The use of conditioned medium as an alternative option to stem cell therapy has been suggested in some studies.…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stromal Cells Derived Conditioned Medium in Pulmonary Fibrosis: A Systematic Review and Meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background: A definitive conclusion on the efficacy of mesenchymal stromal cells-derived conditioned medium (MSCs-CM) in pulmonary fibrosis has not yet been reached. Therefore, the present meta-analysis intends to investigate the efficacy of MSCs-CM administration on improvement of pulmonary fibrosis. Methods: An extensive search was performed on the Medline, Embase, Scopus and Web of Science databases by the end of August 2019. Outcomes in the present study included pulmonary fibrosis score, lung collagen deposition, lung collagen expression, transforming growth factor β1 (TGF-β1) expression and interleukin-6 expression. Finally, the data were pooled and an overall standardized mean difference (SMD) with a 95% confidence interval (CI) was reported. Results: Data from seven studies were included. Analyses showed that administration of MSCs-CM significantly improved pulmonary fibrosis (SMD = -2.36; 95% CI: -3.21, -1.51). MSCs-CM administration also attenuated lung collagen deposition (SMD = -1.70; 95% CI: -2.18, -1.23) and decreased expression of type I collagen (SMD = -6.27; 95% CI: -11.00, -1.55), type III collagen (SMD = -5.16; 95% CI: -9.86, -0.47), TGF- β1 (SMD = -3.36; 95% CI: - 5.62, -1.09) and interleukin-6 (SMD = -1.69; 95% CI: - 3.14, -0.24). Conclusion: The present meta-analysis showed that administration of MSCs-CM improves pulmonary fibrosis. It seems that the effect of MSCs-CM was mediated by reducing collagen deposition as well as inhibiting the production of inflammatory chemokines such as TGF-β1 and interleukin 6 (IL-6). Since there is no evidence on the efficacy of MSCs-CM in large animals, further studies are needed to translate the finding to clinical studies.

show abstract

The secretome of lung resident mesenchymal stem cells is anti-fibrotic in vitro and in vivo

Cited by 5 publications

References 0 publications

The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review

The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review

Potential Cell-Based and Cell-Free Therapy for Patients with COVID-19

Mesenchymal Stromal Cells Derived Conditioned Medium in Pulmonary Fibrosis: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About